199. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-1677.
200. Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrou√©e-Durantel S, Villeneuve JP, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005;41:1391-1398.
201. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-639.
202. Kim JW, Park SH, Louie SG. Telbivudine: a novel nucleoside analog for chronic hepatitis B. Ann Pharmacother 2006;40:472-478.
203. Jones R, Nelson M. Novel anti-hepatitis B agents: A focus on telbivudine. Int J Clin Pract 2006;60:1295-1299.
204. Bryant ML, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001;45:229-235.
205. Hernandez-Santiago B, Placidi L, Cretton-Scott E, Faraj A, Bridges EG, Bryant ML, et al. Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob Agents Chemother 2002;46:1728-1733.
206. Standring DN, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 2001;12(Suppl 1):119-129.
207. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-495.
208. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-2588.
209. Moon YM, Hwang SG, Kim BS, Rim KS, Cho M, Kim DJ, et al. The Efficacy and Safety of Telbivudine in Korean Patients with Chronic Hepatitis B. Korean J Hepatol 2007;13:503-512.
210. Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, et al. Treatment of hepatitis B e antigen positive chronic hepatitis B with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007;147:745-754.
211. Zheng MH, Shi KQ, Dai ZJ, Ye C, Chen YP. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. Clin Ther 2010;32:649-658.
212. Liang J, Han T, Xiao SX. Telbivudine treatment on cirrhosis resulting from chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2009;17:24-27.
213. Chan HLY, Hsu C-W, Sarin S, Suh DJ, Piravisuth T, Ganed E, et al. Efficacy and safety of telbivudine versus lamivudine in the treatment of decompensated chronic hepatitis B for 2 years. [Abstract]. Hepatol Int 2010;4:146.
214. Zeuzem S, Gane E, Liaw YF, Lim SG, DiBiscelgie A, Buti M, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009;51:11-20.
215. Sharon A, Chu CK. Understanding the molecular basis of HBV drug resistance by molecular modeling. Antiviral Res 2008;80:339-353.
216. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-536.
217. Lai CL, Lim SG, Brown NA, Zhou XJ, Lloyd DM, Lee YM, et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 2004;40:719-726.
218. Zhou XJ, Lloyd DM, Chao GC, Brown NA. Absence of food effect on the pharmacokinetics of telbivudine

<PAGE>107